AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 31 min read$NTRA

Chapman Steven Leonard sold $526K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 1,273 shares of Natera, Inc. (NTRA) at $413.31 ($0.53M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Oct 3, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 3, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NTRA
Bearish
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRABearishLow
01

Why it matters

The disclosure provides new, material information about insider sentiment, which may influence short‑term trading decisions.

02

Market read

An insider sale by the CEO is a noteworthy event for traders monitoring Natera's stock, though the monetary size is modest.

03

What to watch

The 10b5-1 plan pre‑arranged nature may mitigate negative interpretation.

Relevance 4/10Novelty 4/10Timing: post‑market filing

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CEO's recent sale.

Company-level read

Ticker impact

$NTRABearishMedium confidence
Context

CEO Steven Leonard sold 1,273 shares for $526K via a 10b5-1 plan, reducing his holdings to 96,926 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

Insider sales, especially by a CEO, are often viewed as a negative signal, though the amount is modest relative to the company's market cap.

Market effects

Sector

Minimal impact on the broader genetic testing sector.

Regional

Limited to U.S. markets where Natera trades.

Global

Low; the filing does not affect global market dynamics.

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing and not indicative of company fundamentals.

Key entities

  • Person
    Steven Leonard

    CEO and President of Natera, Inc.

  • Company
    Natera, Inc.

    Genomics testing company listed on NASDAQ.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTRA insider trading history →

Related articles

OCT 6
$NTRAMedAI 8/10

Why is Natera stock sliding today?

Natera (NTRA) stock fell 6.0% after hitting a 52-week high, despite positive news. Citi raised its price target to $480, and Natera announced new data and a trial. Insider selling and high valuation contributed to the decline. The broader market advanced, indicating the move was company-specific.

investing.com2 min
SEP 23
$NTRAHighAI 9/10

We flagged it early: This diagnostics stock is up +22% after a regulatory win

Natera (NTRA) shares rose 4.5% to a 52-week high of $387.44 after Japan's PMDA approved its Signatera test for bladder cancer. The stock is up 22% since early September. Natera reported record Signatera unit additions and 37.7% revenue growth. Marvell (MRVL) also gained, up 24.7% this month. Investing.com's AI strategies outperformed benchmarks, with Healthcare Heroes up 2.67% this month.

investing.com2 min
SEP 22
$NTRAMedAI 8/10

Why Is Natera (NTRA) Stock Soaring Today

Natera (NTRA) stock rose 5.2% after Japan approved its Signatera test for bladder cancer. The company plans a 2027 commercial launch in Japan. Shares later cooled to $387.44, up 4.5%. Natera's revenue grew 38.8% YoY to $696.6M, but its loss widened to $0.60 per share, missing estimates.

financialcontent.com2 min